stockportfolio.pro
NewAmsterdam Pharma Company N.V. (NAMS)
Healthcare · Biotechnology · NasdaqGM
NewAmsterdam Pharma Company N.V. revenue & earnings — last 5 fiscal years
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $102.69M | $14.09M | $45.56M | $22.50M |
| Gross profit | — | — | — | — | — |
| Net income | $-41.78M | $-22.63M | $-176.94M | $-241.60M | $-203.82M |
| Net margin | — | -22.0% | -1255.8% | -530.3% | -905.7% |
Source: NewAmsterdam Pharma Company N.V. SEC filings (10-K).
Explore 5 years of NewAmsterdam Pharma Company N.V. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NAMS in your portfolio →
NewAmsterdam Pharma Company N.V. financial history by metric
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V. — frequently asked questions
What is NewAmsterdam Pharma Company N.V.'s revenue?
NewAmsterdam Pharma Company N.V. (NAMS) reported revenue of $22.50M for fiscal year 2025, down 50.6% from the prior year, according to its SEC filings.
Is NewAmsterdam Pharma Company N.V. profitable?
No — NAMS reported a net loss of $-203.82M in fiscal 2025.
What is NAMS's P/E ratio?
NewAmsterdam Pharma Company N.V. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does NewAmsterdam Pharma Company N.V. have?
As of fiscal year 2025, NAMS carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is NewAmsterdam Pharma Company N.V.'s market cap?
NewAmsterdam Pharma Company N.V. (NAMS) has a market capitalization of about $3.54B, based on the latest data in our nightly-refreshed cache.
When does NewAmsterdam Pharma Company N.V.'s fiscal year end?
NAMS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from NewAmsterdam Pharma Company N.V.'s official SEC filings (10-K and 10-Q), covering 5 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.